Clay Siegall is a genetic expert and an experienced executive leader. The scientist is the president and CEO of Seattle Genetics, a biotech company focusing on developing cancer therapies. He co-founded the company in 1998. Over the last two years, he has been involved in helping the firm come up with quality cancer treatments and enhancing the funding needed by the company to further its research.
The company’s first commercial cancer therapy was known as ADCETRIS (brentuximab vedotin). The drug is used to treat patients experiencing the failure of auto-HSCT, failure of at least two prior multi-agent chemotherapy regimens, and systemic anaplastic large cell lymphoma. The drug is the first in the line of many antibody-drug conjugates being developed by the company. It was approved in 2011 by FIDA. The drug has already been approved in over 60 countries worldwide. This information was originally mentioned on Seattle Genetic’s website as outlined in the following link http://www.seattlegenetics.com/adcetris
Dr. Siegall’s strategic business plans have been central to the company’s fundraising goals. Seattle Genetics has been able to raise over $325 million from licensing its ADC technology to other biotech firms such as AbbVie, Pfizer, GlaxoSmithKline, and Genentech. These deals have resulted into the development of over 20 ADCs. Apart from selling the ADC technology to other firms, Dr. Siegall has also been responsible for overseeing the initial public offering conducted by Seattle Genetics in 2001. The IPO and private funding have seen the company raise over $1.2 billion in the last 20 years.
Before co-founding Seattle Genetics, Clay worked for various institutions as a researcher. These organizations include the National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute, and National Institute of Health. In the research facilities, he focused on cancer and cancer therapies. Dr. Siegall’s experience in the field has also seen him sit on the boards of leading firms such as Ultragenyx Pharmaceutical and Alder BioPharmaceutical.
Many media outlets have also hosted the expert. For instance, he has been to CNBC where discussed his company’s plans for treating non-Hodgkin’s lymphoma. CNBC’s Meg Tirrell hosted him. The scientist is confident that his firm’s therapies would revolutionize the treatment of the disease. Dr. Seigall has active Facebook and Twitter accounts, which he uses to communicate with his followers and friends.